Actelion to cut costs, jobs to help specialty focus
ZURICH, July 12
ZURICH, July 12 (Reuters) - Europe's leading biotech company Actelion said on Thursday it planned to cut up to 135 jobs as part of cost-cutting to focus on research in pulmonary arterial hypertension, or PAH.
Actelion, which employs 2500 people globally, has been banking on lung and heart drug macitentan as a successor to its blockbuster Tracleer, which currently accounts for around 90 percent of group sales and goes off patent in 2015.
The firm said it was minimising the number of potential redundancies through natural attrition, early retirements and similar measures.
(Reporting by Catherine Bosley)
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |